Caroline E Nunes-Xavier1,2, Javier C Angulo3,4, Rafael Pulido1,5, José I López6,7,8. 1. Biomarkers in Cancer Unit, Biocruces-Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. 2. Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. 3. Department of Urology, University Hospital of Getafe, Getafe, Madrid, Spain. 4. Clinical Department, European University of Madrid, Laureate Universities, Madrid, Spain. 5. IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain. 6. Biomarkers in Cancer Unit, Biocruces-Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. jilpath@gmail.com. 7. Department of Pathology, Cruces University Hospital, Plaza de Cruces s/n, 48903, Barakaldo, Bizkaia, Spain. jilpath@gmail.com. 8. Department of Medical-Surgical Specialties, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain. jilpath@gmail.com.
Abstract
PURPOSE OF REVIEW: Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient's life. RECENT FINDINGS: Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing. We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.
PURPOSE OF REVIEW: Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient's life. RECENT FINDINGS: Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing. We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.
Authors: Maria Libera Ascierto; Tracee L McMiller; Alan E Berger; Ludmila Danilova; Robert A Anders; George J Netto; Haiying Xu; Theresa S Pritchard; Jinshui Fan; Chris Cheadle; Leslie Cope; Charles G Drake; Drew M Pardoll; Janis M Taube; Suzanne L Topalian Journal: Cancer Immunol Res Date: 2016-08-04 Impact factor: 11.151
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: R Houston Thompson; Haidong Dong; Christine M Lohse; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531
Authors: Gorka Larrinaga; Jon Danel Solano-Iturri; Peio Errarte; Miguel Unda; Ana Loizaga-Iriarte; Amparo Pérez-Fernández; Enrique Echevarría; Aintzane Asumendi; Claudia Manini; Javier C Angulo; José I López Journal: Cancers (Basel) Date: 2021-02-07 Impact factor: 6.639